Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib.
Cancer Treatment and Research Communications（2019）
摘要
SRT and TKI continuation may be considered for select patients with EGFR mutant NSCLC and oligo-progression on EGFR TKI therapy.
更多查看译文
关键词
Stereotactic radiosurgery,Oligoprogression,EGFR,Erlotinib
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要